LIXT Lixte Biotechnology Holdings Inc.

2.89
-0.01  -0%
Previous Close 2.9
Open 2.83
52 Week Low 2.36
52 Week High 7.86
Market Cap $39,486,821
Shares 13,663,260
Float 6,050,451
Enterprise Value $35,657,396
Volume 27,337
Av. Daily Volume 261,286
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
LB-100
Myelodysplastic Syndromes (MDS)
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
LB-100
Small Cell Lung Cancer
Phase 1
Phase 1
Phase 1 commencement of enrollment announced June 2, 2021.
LB-100
Glioblastoma Multiforme
Phase 2
Phase 2
Phase 2 trial ongoing.

Latest News

    • Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal models
    • Due to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit in patients may be seen in this early-stage clinical trial

    EAST SETAUKET, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the enrollment of the first patient in a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial will assess the combination of Lixte's first-in-class protein phosphatase 2A (PP2A) inhibitor LB-100…

    • Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal models
    • Due to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit in patients may be seen in this early-stage clinical trial

    EAST SETAUKET, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the enrollment of the first patient in a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial will assess the combination of Lixte's first-in-class protein phosphatase 2A (PP2A) inhibitor LB-100 with a standard regimen for previously untreated, extensive stage-disease small cell lung cancer (ED-SCLC) (NCT04560972).

    John S. Kovach, M.D., Lixte founder and chief executive officer, said, "In collaboration with City of Hope, we are eager to pursue our well-grounded rationale for adding LB-100 to a standard ED-SCLC regimen of carboplatin and etoposide chemotherapy plus atezolizumab to enhance effectiveness. In preclinical studies, the malignant cells of this uniformly fatal cancer are genetically sensitive to PP2A inhibition by a process termed synthetic lethality and the effectiveness of the standard regimen is enhanced by LB-100.

    "Small cell lung cancer comprises approximately 15% of all lung cancers worldwide with about 30,000 new cases annually in the U.S.," Dr. Kovach continued. "The median survival of patients with this especially aggressive type of lung cancer, even with current ‘best' therapy, is approximately nine months. Because of such rapid disease progression, the therapeutic benefit of adding LB-100 to the standard treatment may be seen early on in this Phase 1b clinical trial."

    Ravi Salgia, M.D., Ph.D., City of Hope's Arthur & Rosalie Kaplan Chair in Medical Oncology, said, "We are hopeful that this trial testing a potentially more effective therapeutic combination could provide another treatment option for small cell lung cancer patients. It is a disease that is currently difficult to treat, particularly after a patient has relapsed, so more therapeutic options are needed."

    About the Study

    In the Phase 1b trial of LB-100 for the treatment of ED-SCLC, Lixte's lead compound will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC. The dose of LB-100 will be escalated with fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D). Patient entry will then be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm its safety and to look for objective evidence of potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free-survival and overall survival. The study is open at City of Hope in Duarte, California.

    About City of Hope

    City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope's translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHopeTM, a wholly owned subsidiary, was launched in 2019 and is dedicated to serving employers and their health care partners by providing access to City of Hope's exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation's "Best Hospitals" in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on FacebookTwitterYouTube or Instagram.

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. www.lixte.com

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

    Lixte Contact:



    General Phone: (631) 830-7092

    Investor Phone: (888) 289-5533



    Primary Logo

    View Full Article Hide Full Article
  1. May 19 - 20, 2021

    Presentation times and weblinks released for over 60 presenting companies

    NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wednesday and Thursday, May 19 - 20, 2021. The links can also be found at www.sidoticonference.com/events.

    Group Presentation Schedule

    (click on the company name to register & watch)

    Wednesday, May 19th, 2021 (Day 1)

    *All Times EDT

    8:30-9:00

    Lincoln Education Services (LINC)

    Bassett Furniture (BSET)

    Real Luck Group (LUCK)

    ****

    9:15-9:45

    Medexus Pharmaceuticals (MDP)

    Hill International (HIL)

    Pangaea Logistics Solutions (PANL)

    Zoom Telephonics dba "Minim" (MINM)

    10:00-10:30

    Flexsteel Industries

    May 19 - 20, 2021

    Presentation times and weblinks released for over 60 presenting companies

    NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wednesday and Thursday, May 19 - 20, 2021. The links can also be found at www.sidoticonference.com/events.

    Group Presentation Schedule

    (click on the company name to register & watch)

    Wednesday, May 19th, 2021 (Day 1)

    *All Times EDT

    8:30-9:00

    Lincoln Education Services (LINC)

    Bassett Furniture (BSET)

    Real Luck Group (LUCK)

    ****

    9:15-9:45

    Medexus Pharmaceuticals (MDP)

    Hill International (HIL)

    Pangaea Logistics Solutions (PANL)

    Zoom Telephonics dba "Minim" (MINM)

    10:00-10:30

    Flexsteel Industries (FLXS)

    Limbach Holdings (LMB)

    STRATTEC Security Corp (STRT)

    VIQ Solutions (VQS)

    10:45-11:15

    The Eastern Company (EML)

    Orion Group Holdings (ORN)

    MDC Partners (MDCA)

    AstroNova, Inc. (ALOT)

    11:30-12:00

    Acme United Corp (ACU)

    ****

    DHI Group (DHX)

    Tinybeans (TNY)

    12:15-12:45

    PCTEL, Inc (PCTI)

    Verb Technology Company (VERB)

    Golden Valley Mines Ltd. (GZZ)

    VolitionRx Ltd. (VNRX)

    1:00-1:30

    Amesite Inc. (AMST)

    UGE International (UGE)

    Wayside Technology (WSTG)

    Energy Focus Inc. (EFOI)

    1:45-2:15

    Nanotech Security (NTS)

    Oblong Inc. (OBLG)

    GSE Systems (GVP)

    ****

    2:30-3:00

    Liberty Defense (SCAN)

    LXRandCo, Inc (LXR)

    Solar Alliance Energy (SOLR)

    PopReach Corp (POPR)

    3:15-3:45

    Trecora Resources (TREC)

    OneSoft Solutions (OSS)

    ****

    Monaker Group (MKGI)

    4:00-4:30

    Black Diamond Group (BDI)

    good natured Products (GDNP)

    American Battery Metals Corporation (ABML)

    G5 Entertainment (GENTF)

    Thursday, May 20th, 2021 (Day 2)

    *All Times EDT

    8:30-9:00

    Lifetime Brands (LCUT)

    Commercial Vehicle Group (CVGI)

    u-blox Holding (UBXN)

    ****

    9:15-9:45

    ****

    Armstrong Flooring (AFI)

    Tessco Technologies (TESS)

    Silvercrest Asset Management Group (SAMG)

    10:00-10:30

    Apollo Endosurgery (APEN)

    Civeo Corp (CVEO)

    Williams Industrial Services Group (WLMS)

    ****

    10:45-11:15

    Assure Holdings (ARHH)

    Stabilis Solutions (SLNG)

    Tecnoglass, Inc. (TGLS)

    Jerash Holdings (JRSH)

    11:30-12:00

    Star Equity Holdings (STRR)

    Ur-Energy Inc. (URG)

    Gaia, Inc. (GAIA)

    GSI Technology (GSIT)

    12:15-12:45

    Computer Task Group (CTG)

    Diebold Nixdorf (DBD)

    Lixte Biotechnology (LIXT)

    POET Technologies (PTK)

    1x1s Only - No Presentation

    Blueknight (BKEP) || LSB Industries (LXU)

    About Sidoti

    For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $4 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a small and microcap focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. We serve 500+ institutional clients in North America, including many leading managers of portfolios with $200 million to $2 billion of AUM. Sidoti promotes meaningful interaction between issuers and investors in the small and microcap space through our conferences (www.sidoticonference.com) and the hundreds of non-deal roadshows we host each year.

    Contact

    Sidoti Events Team
    212-453-7031

    SOURCE: Sidoti & Company, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/647987/Sidoti-Microcap-Virtual-Conference

    View Full Article Hide Full Article
  2. EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair.

    Dr. John S. Kovach, Founder and CEO of Lixte, said "We are pleased to welcome Regina to our board of directors. We look forward to benefiting from her decades of experience in public accounting. As our company expands, her expertise in compliance, taxation and internal control implementation is a valuable addition to our board of directors."

    Ms. Brown began her accounting practice over 30 years ago. Currently, her practice has a wide range of clients, varying in size, industry, and geographic…

    EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair.

    Dr. John S. Kovach, Founder and CEO of Lixte, said "We are pleased to welcome Regina to our board of directors. We look forward to benefiting from her decades of experience in public accounting. As our company expands, her expertise in compliance, taxation and internal control implementation is a valuable addition to our board of directors."

    Ms. Brown began her accounting practice over 30 years ago. Currently, her practice has a wide range of clients, varying in size, industry, and geographic locations. They include large national corporations listed on the New York Stock Exchange, as well as smaller regional businesses. Other clients consist of professionals, wholesalers, and high net worth individuals. Many of her clients have international and cross-border operations.

    As a consequence of her depth of experience, she regularly assists other professionals with their clients' issues and performs tax research and analysis in connection with litigation and other matters including tax and accounting with respect to mergers and acquisitions and implementation of internal controls. In addition, international tax matters and compliance have become a significant part of her practice. She is a member in good standing of California Society of CPAs and the American Institute of Certified Public Accountants.

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

    Lixte Contact:



    General Phone: (631) 830-7092

    Investor Phone: (888) 289-5533



    Primary Logo

    View Full Article Hide Full Article
  3. Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments

    EAST SETAUKET, NY, May 04, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the Sidoti & Company LLC Virtual Microcap Conference being held May 19-20, 2021. Lixte Founder and CEO John S. Kovach, M.D. will present on Thursday, May 20 at 12:15 p.m. ET. Investors may attend Lixte's virtual presentation by visiting the conference registration webpage.

    "During my presentation at the Sidoti conference, I will focus on the key advantages…

    Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments

    EAST SETAUKET, NY, May 04, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the Sidoti & Company LLC Virtual Microcap Conference being held May 19-20, 2021. Lixte Founder and CEO John S. Kovach, M.D. will present on Thursday, May 20 at 12:15 p.m. ET. Investors may attend Lixte's virtual presentation by visiting the conference registration webpage.

    "During my presentation at the Sidoti conference, I will focus on the key advantages of our lead compound LB-100," said Dr. Kovach. "At present we are not aware of any clinical competition for LB-100, and we benefit from a broad, high-value IP asset portfolio. The potential market value for our product is very large as many preclinical studies by outstanding independent investigators indicate that LB-100 appears to enhance the efficacy of chemotherapy, radiotherapy and immunotherapy."

    Lixte's product pipeline presently includes three clinical studies and one pharmacology study of LB-100 for four of the most aggressive cancers: myelodysplastic (MDS) syndromes, advanced soft tissue sarcomas (ASTS), small cell lung cancer (SCLC), and glioblastoma multiforme (GBM). The total market for these cancer targets exceeds $5 billion.

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

    Lixte Contact:



    General Phone: (631) 830-7092

    Investor Phone: (888) 289-5533



    Primary Logo

    View Full Article Hide Full Article
    • Lixte's pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100

    EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Global Small Cap Conference being held May 13-14, 2021. Lixte will be presenting on Thursday, May 13, 1:00-1:20 pm Eastern Time. Investors may register and consult the conference agenda by visiting the event website.

    John S. Kovach, M.D., Lixte founder and chief executive officer, commented, "Our lead drug candidate, LB-100, is currently being studied in clinical investigations targeting…

    • Lixte's pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100

    EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Global Small Cap Conference being held May 13-14, 2021. Lixte will be presenting on Thursday, May 13, 1:00-1:20 pm Eastern Time. Investors may register and consult the conference agenda by visiting the event website.

    John S. Kovach, M.D., Lixte founder and chief executive officer, commented, "Our lead drug candidate, LB-100, is currently being studied in clinical investigations targeting some of the most aggressive cancers. If the improvement of standard treatments for diverse cancers seen in multiple preclinical studies of by LB-100 is documented in the clinic, this first-in-class compound will be an important advance in cancer therapy."

    Lixte's LB-100 clinical targets are myelodysplastic (MDS) syndromes, advanced soft tissue sarcomas (ASTS), small cell lung cancer (SCLC), and glioblastoma multiforme (GBM). The total market for these cancer targets exceeds $5 billion.

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many cancers and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Much cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at dose levels associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. Lixte's LB-100 lead compound. No competitors using this approach are known to Lixte. Additional information on Lixte and its research activities is available at www.lixte.com.

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

    Lixte Contact:



    General Phone: (631) 830-7092

    Investor Phone: (888) 289-5533



    Primary Logo

    View Full Article Hide Full Article
View All Lixte Biotechnology Holdings Inc. News